Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry
Ryan P Barbaro,Graeme MacLaren,Philip S Boonstra,Theodore J Iwashyna,Arthur S Slutsky,Eddy Fan,Robert H Bartlett,Joseph E Tonna,Robert Hyslop,Jeffrey J Fanning,Peter T Rycus,Steve J Hyer,Marc M Anders,Cara L Agerstrand,Katarzyna Hryniewicz,Rodrigo Diaz,Roberto Lorusso,Alain Combes,Daniel Brodie,Extracorporeal Life Support Organization,Peta Alexander,Nicholas Barrett,Jan Bělohlávek,Dale Fisher,John Fraser,Ali Ait Hssain,Jae Sung Jung,Michael McMullan,Yatin Mehta,Mark T Ogino,Matthew L Paden,Kiran Shekar,Christine Stead,Yasir Abu-Omar,Vanni Agnoletti,Anzila Akbar,Huda Alfoudri,Carlos Alviar,Vladimir Aronsky,Erin August,Georg Auzinger,Hilda Aveja,Rhonda Bakken,Joan Balcells,Sripal Bangalore,Bernard W Barnes,Alaiza Bautista,Lorraine L Bellows,Felipe Beltran,Peyman Benharash,Marco Benni,Jennifer Berg,Pietro Bertini,Pablo Blanco-Schweizer,Melissa Brunsvold,Jenny Budd,Debra Camp,Mark Caridi-Scheible,Edmund Carton,Elena Casanova-Ghosh,Anthony Castleberry,Christopher T Chipongian,Chang Woo Choi,Alessandro Circelli,Elliott Cohen,Michael Collins,Scott Copus,Jill Coy,Brandon Crist,Leonora Cruz,Mirosław Czuczwar,Mani Daneshmand,Daniel Davis Ii,Kim De la Cruz,Cyndie Devers,Toni Duculan,Lucian Durham,Subbarao Elapavaluru,Carlos V Elzo Kraemer,EdmÍlson Cardoso Filho,Jillian Fitzgerald,Giuseppe Foti,Matthew Fox,David Fritschen,David Fullerton,Elton Gelandt,Stacy Gerle,Marco Giani,Si Guim Goh,Sara Govener,Julie Grone,Miles Guber,Vadim Gudzenko,Daniel Gutteridge,Jennifer Guy,Jonathan Haft,Cameron Hall,Ibrahim Fawzy Hassan,Rubén Herrán,Hitoshi Hirose,Abdulsalam Saif Ibrahim,Don Igielski,Felicia A Ivascu,Jaume Izquierdo Blasco,Julie Jackson,Harsh Jain,Bhavini Jaiswal,Andrea C Johnson,Jenniver A Jurynec,Norma M Kellter,Adam Kohl,Zachary Kon,Markus Kredel,Karen Kriska,Chandra Kunavarapu,Oude Lansink-Hartgring,Jeliene LaRocque,Sharon Beth Larson,Tracie Layne,Stephane Ledot,Napolitan Lena,Jonathan Lillie,Gösta Lotz,Mark Lucas,Lee Ludwigson,Jacinta J Maas,Joanna Maertens,David Mast,Scott McCardle,Bernard McDonald,Allison McLarty,Chelsea McMahon,Patrick Meybohm,Bart Meyns,Casey Miller,Fernando Moraes Neto,Kelly Morris,Ralf Muellenbach,Meghan Nicholson,Serena O'Brien,Kathryn O'Keefe,Tawnya Ogston,Gary Oldenburg,Fabiana M Oliveira,Emily Oppel,Diego Pardo,Sara J Parker,Finn M Pedersen,Crescens Pellecchia,Jose A S Pelligrini,Thao T N Pham,Ann R Phillips,Tasneem Pirani,Paweł Piwowarczyk,Robert Plambeck,William Pruett,Brittany Quandt,Kollengode Ramanathan,Alejandro Rey,Christian Reyher,Jordi Riera Del Brio,Rachel Roberts,David Roe,Peter P Roeleveld,Janet Rudy,Luis F Rueda,Emanuele Russo,Jesús Sánchez Ballesteros,Nancy Satou,Mauricio Guidi Saueressig,Paul C Saunders,Margaret Schlotterbeck,Patricia Schwarz,Nicole Scriven,Alexis Serra,Mohammad Shamsah,Lucy Sim,Alexandra Smart,Adam Smith,Deane Smith,Maggie Smith,Neel Sodha,Michael Sonntagbauer,Marc Sorenson,Eric B Stallkamp,Allison Stewart,Kathy Swartz,Koji Takeda,Shaun Thompson,Bridget Toy,Divina Tuazon,Makoto Uchiyama,Obiora I Udeozo,Scott van Poppel,Corey Ventetuolo,Leen Vercaemst,Nguyen V Vinh Chau,I-Wen Wang,Carrie Williamson,Brock Wilson,Helen Winkels
DOI: https://doi.org/10.1016/S0140-6736(20)32008-0
2020-10-10
Abstract:Background: Multiple major health organisations recommend the use of extracorporeal membrane oxygenation (ECMO) support for COVID-19-related acute hypoxaemic respiratory failure. However, initial reports of ECMO use in patients with COVID-19 described very high mortality and there have been no large, international cohort studies of ECMO for COVID-19 reported to date. Methods: We used data from the Extracorporeal Life Support Organization (ELSO) Registry to characterise the epidemiology, hospital course, and outcomes of patients aged 16 years or older with confirmed COVID-19 who had ECMO support initiated between Jan 16 and May 1, 2020, at 213 hospitals in 36 countries. The primary outcome was in-hospital death in a time-to-event analysis assessed at 90 days after ECMO initiation. We applied a multivariable Cox model to examine whether patient and hospital factors were associated with in-hospital mortality. Findings: Data for 1035 patients with COVID-19 who received ECMO support were included in this study. Of these, 67 (6%) remained hospitalised, 311 (30%) were discharged home or to an acute rehabilitation centre, 101 (10%) were discharged to a long-term acute care centre or unspecified location, 176 (17%) were discharged to another hospital, and 380 (37%) died. The estimated cumulative incidence of in-hospital mortality 90 days after the initiation of ECMO was 37·4% (95% CI 34·4-40·4). Mortality was 39% (380 of 968) in patients with a final disposition of death or hospital discharge. The use of ECMO for circulatory support was independently associated with higher in-hospital mortality (hazard ratio 1·89, 95% CI 1·20-2·97). In the subset of patients with COVID-19 receiving respiratory (venovenous) ECMO and characterised as having acute respiratory distress syndrome, the estimated cumulative incidence of in-hospital mortality 90 days after the initiation of ECMO was 38·0% (95% CI 34·6-41·5). Interpretation: In patients with COVID-19 who received ECMO, both estimated mortality 90 days after ECMO and mortality in those with a final disposition of death or discharge were less than 40%. These data from 213 hospitals worldwide provide a generalisable estimate of ECMO mortality in the setting of COVID-19. Funding: None.